Prodrug activation enzymes in cancer gene therapy

Journal of Gene Medicine

Volumn 2, Issue 3, 2000, Pages 148-164

  Aghi, Manish ^a   Hochberg, Fred ^a   Breakefield, Xandra O ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Cancer; Gene therapy; Prodrug activation; Review article

Indexed keywords

BACTERIA (MICROORGANISMS); MAMMALIA;

ANTINEOPLASTIC AGENT; ENZYME; PRODRUG;

ENZYMOLOGY; GENE THERAPY; GENETICS; HUMAN; METABOLISM; NEOPLASM; REVIEW; TRANSGENE;

ANTINEOPLASTIC AGENTS; ENZYMES; GENE THERAPY; HUMANS; NEOPLASMS; PRODRUGS; TRANSGENES;

EID: 0034186366     PISSN: 1099498X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1521-2254(200005/06)2:3<148::AID-JGM105>3.0.CO;2-Q     Document Type: Review

References (129)

1. Sikora K. Genetic approaches to cancer therapy. Gene Ther 1994; 1: 149-151.
2. Roth JA, Cristiano RJ. Gene therapy for cancer: what have we done and where are we going? J Natl Cancer Inst 1997; 89: 21-39.
3. Roth JA, Swisher SG, Meyn RE. p53 tumor suppressor gene therapy for cancer. Oncology 1999; 13: 148-154.
4. O'Reilly MS, Boehm T, Shing Y, et al. Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell 1997; 88: 277-285.
5. Lin P, Polverini P, Dewhirst M, et al. Inhibition of tumor angiogenesis using a soluble receptor establishes a role for Tie2 in pathologic vascular growth. J Clin Invest 1997; 100: 2072-2078.
6. Simons JW, Mikhak B. Ex-vivo gene therapy using cytokine-transduced tumor vaccines: molecular and clinical pharmacology. Semin Oncol 1998; 25: 661-676.
7. Moscow JA, Huang H, Carter C, et al. Engraftment of MDR1 and NeoR gene-transduced hematopoietic cells after breast cancer chemotherapy. Blood 1999; 94: 52-61.
8. Beausejour CM, Le NL, Letourneau S, et al. Coexpression of cytidine deaminase and mutant dihydrofolate reductase by a bicitronic retroviral vector confers resistance to cytosine arabinoside and methotrexate. Hum Gene Ther 1998; 9: 2537-2544.
9. Connors TA, Whisson ME. Cure of mice bearing advanced plasma cell tumors with aniline mustard: the relationship between glucuronidase activity and tumor sensitivity. Nature 1966; 210: 866-867.
10. Cobb LM, Connors TA, Elson LA, et al. 2,4-Dinitro-5-ethyleneiminobenzamide (CB 1954): a potent and selective inhibitor of the growth of the Walker carcinoma 256. Biochem Pharmacol 1969; 18: 1519-1527.
11. Philpott GW, Shearer WT, Bower RW, et al. Selective cytotoxicity of hapten-substituted cells with an antibody-enzyme conjugate. J Immunol 1973; 111: 921-929.
12. Martin J, Stribbling SM, Poon GK, et al. Antibody-directed enzyme prodrug therapy: pharmacokinetics and plasma levels of the prodrug and drug in a phase I clinical trial. Cancer Chemother Pharmacol 1997; 40: 189-201.
13. Moolten FL. Tumor chemosensitivity conferred by inserted herpes thymidine kinase genes: a paradigm for a prospective cancer control strategy. Cancer Res 1986; 46: 5276-5281.
14. Faulds D, Heel RC. Ganciclovir: a review of its antiviral activity, pharmacokinetic properties, and therapeutic effciacy in cytomegalovirus infections. Drugs 1990; 39: 597-638.
15. Ilsley DD, Lee S, Miller WH, et al. Acyclic guanosine analogs inhibit DNA polymerases alpha, delta, and epsilon with very different potencies and have unique mechanisms of action. Biochemistry 1995; 34: 2504-2510.
16. Moolten FL, Wells JM. Curability of tumors bearing thymidine kinase genes transferred by retroviral vectors. J Natl Cancer Inst 1990; 82: 297-300.
17. Ezzeddine ZD, Martuza RL, Platika D, et al. Selective killing of glioma cells in culture and in vivo following retrovirus transfer of the herpes simplex virus thymidine kinase gene. New Biologist 1991; 3: 608-614.
18. Freeman SM, Abboud CN, Whartenby KA, et al. The 'bystander effect': tumor regression when a fraction of the tumor mass is genetically modified. Cancer Res 1993; 53: 5274-5283.
19. Takamiya Y, Short MP, Ezzeddine ZD, et al. Gene therapy of malignant brain tumors: a rat glioma line bearing the herpes simplex virus type 1-thymidine kinase gene and wild type retrovirus kills other tumor cells. J Neurosci Res. 1992; 33: 493-503.
20. Rainov NG, Kramm CM, Aboody-Guterman K, et al. Retrovirus-mediated gene therapy of experimental brain neoplasms using the herpes simplex virus-thymidine kinase/ganciclovir paradigm. Cancer Gene Ther 1996; 3: 99-106.
21. Culver KW, Ram Z, Wallbridge S, et al. In vivo gene transfer with retroviral vector-producer cells for treatment of experimental brain tumors. Science 1992; 256: 1550-1552.
22. Bi WL, Parysek LM, Warnick R, et al. In vitro evidence that metabolic cooperation is responsible for the bystander effect observed with HSV tk retroviral gene therapy. Hum Gene Ther 1993; 4: 725-731.
23. Ishii-Morita H, Agbaria R, Mullen CA, et al. Mechanism of 'bystander effect' killing in the herpes simplex thymidine kinase gene therapy model of cancer treatment. Gene Ther 1997; 4: 244-251.
24. Fick J, Barker FG, Dazin P, et al. The extent of heterocellular communication mediated by gap junctions is predictive of bystander tumor cytotoxicity in vitro. Proc Natl Acad Sci U S A 1995; 92: 11071-11075.
25. Vrionis FD, Wu JK, Waltzman M, et al. The bystander effect exerted by tumor cells expressing the herpes simplex virus thymidine kinase (HSV-TK) gene is dependent on connexin expression and cell communication via gap junctions. Gene Ther 1997; 4: 577-585.
26. Park JY, Elshami AA, Amin K, et al. Retinoids augment the bystander effect in vitro and in vivo in herpes simplex virus thymidine kinase/ganciclovir-mediated gene therapy. Gene Ther 1997; 4: 909-917.
27. Touraine RL, Ishii-Morita H, Ramsey WJ, et al. The bystander effect in the HSVtk/ganciclovir system and its relationship to gap junctional communication. Gene Ther 1998; 5: 1705-1711.
28. Touraine RL, Vahanian N, Ramsey WJ, et al. Enhancement of the herpes simplex virus thymidine kinase/ganciclovir bystander effect and its antitumor efficacy in vivo by pharmacologic manipulation of gap junctions. Hum Gene Ther 1998; 9: 2385-2391.
29. Dilber MS, Abedi MR, Christensson B, et al. Gap junctions promote the bystander effect of herpes simplex virus thymidine kinase in vivo. Cancer Res 1997; 67: 1523-1528.
30. Samejima Y, Meruelo D. 'Bystander killing' induces apoptosis and is inhibited by forskolin. Gene Ther 1995; 2: 50-58.
31. Wei SJ, Chao Y, Shih YL, et al. Involvement of fas (CD95/APO-1) and Fas ligand in apoptosis induced by ganciclovir treatment of tumor cells transduced with herpes simplex virus thymidine kinase. Gene Ther 1999; 6: 420-431.
32. Ram Z, Walbridge S, Shawker T, et al. The effect of thymidine kinase transduction and ganciclovir therapy on tumor vasculature and growth of 9L gliomas in rats. J Neurosurg 1994; 81: 256-260.
33. Barba D, Hardin J, Sadelain M, et al. Development of anti-tumor immunity following thymidine kinase-mediated killing of experimental brain tumors. Proc Natl Acad Sci U S A 1994; 91: 4348-4352.
34. Gagandeep S, Brew R, Green B, et al. Prodrug-activated gene therapy: involvement of an immunological component in the 'bystander effect'. Cancer Gene Ther 1996; 3: 83-88.
35. Kianmanesh AR, Perrin H, Panis Y, et al. A 'distant' bystander effect of suicide gene therapy: regression of nontransduced tumor together with a distant transduced tumor. Hum Gene Ther 1997; 8: 1807-1814.
36. Caruso M, Panis Y, Gagandeep S, et al. Regression of established macroscopic liver metastases after in situ transduction of a suicide gene. Proc Natl Acad Sci U S A 1993; 90: 7024-7028.
37. Engelmann C, Panis Y, Bolard J, et al. Liposomal encapsulation of ganciclovir enhances the efficacy of herpes simplex virus type 1 thymidine kinase suicide gene therapy against hepatic tumors in rats. Hum Gene Ther 1999; 10: 1545-1551.
38. Van der Eb MM, Cramer SJ, Vergouwe Y, et al. Severe hepatic dysfunction after adenovirus-mediated transfer of the herpes simplex virus thymidine kinase gene and ganciclovir administration. Gene Ther 1998; 5: 451-458.
39. Shewach DS, Zerbe LK, Hughes TL, et al. Enhanced cytotoxicity of antiviral drugs mediated by adenovirus directed transfer of the herpes simplex virus thymidine kinase gene in rat glioma cells. Cancer Gene Ther 1994; 1: 107-112.
40. Balzarini J, Degreve B, Andrei G, et al. Superior cytostatic activity of the ganciclovir elaidic acid ester due to the prolonged intracellular retention of ganciclovir anabolites in herpes simplex virus type 1 thymidine kinase gene-transfected tumor cells. Gene Ther 1998; 5: 419-426.
41. Degreve B, De Clerq E, Balzarini J. Bystander effect of purine nucleoside analogues in HSV-1tk suicide gene therapy is superior to that of pyrimidine nucleoside analogues. Gene Ther 1999; 6: 162-170.
42. Black ME, Newcomb TG, Wilson HP, et al. Creation of drug-specific herpes simplex virus type 1 thymidine kinase mutants for gene therapy. Proc Natl Acad Sci U S A 1996; 93: 3525-3529.
43. Degreve B, Andrei G, Izquierdo M, et al. Varicella-zoster virus thymidine kinase gene and antiherpetic pyrimidine nucleoside analogues in a combined gene/chemotherapy treatment for cancer. Gene Ther 1997; 4: 1107-1114.
44. Loubiere L, Tiraby M, Cazaux C, et al. The equine herpes virus 4 thymidine kinase is a better suicide gene than the human herpes virus 1 thymidine kinase. Gene Ther 1999; 6: 1638-1642.
45. Kim JH, Kim SH, Kolozsvarky A, et al. Selective enhancement of radiation response of herpes simplex virus thymidine kinase transduced 9L gliosarcoma cells in vitro and in vivo by antiviral agents. Int J Radiat Oncol Biol Phys 1995; 33: 861-868.
46. Tjuvajev JG, Finn R, Watanabe K, et al. Noninvasive imaging of herpes virus thymidine kinase gene transfer and expression: a potential method for monitoring clinical gene therapy. Cancer Res 1996; 56: 4087-4095.
47. Gambhir SS, Barrrio JR, Herschman HR, et al. Assays for noninvasive imaging of reporter gene expression. Nucl Med Biol 1999; 26: 481-409.
48. Kramm CM, Sena-Esteves M, Barnett FH, et al. Gene therapy for brain tumors. Brain Pathol 1995; 5: 345-381.
49. Goldstein DJ, Weller SK. Herpes simplex virus type 1-induced ribonucleotide reductase activity is dispensable for virus growth and DNA synthesis: isolation and characterization of an ICP6 lacZ insertion mutation. J Virol 1988; 62: 196-205.
50. Boviatsis EJ, Park JS, Sena-Esteves M, et al. Long-term survival of rats harboring brain neoplasms treated with ganciclovir and a hepres simplex virus vector that retains an intact thymidine kinase gene. Cancer Res 1994; 54: 5745-5751.
51. Carroll NM, Chase M, Chiocca EA, et al. The effect of ganciclovir on herpes simplex virus-mediated oncolysis. J Surg Res 1997; 69: 413-417.
52. Ram Z, Culver K, Oshiro E, et al. Summary of results and conclusions of the gene therapy of malignant brain tumors: clinical study. J Neurosurg 1995; 82: 343A.
53. Harsh GR, Deisboeck TS, Louis DN, et al. Thymidine kinase activation of ganciclovir in recurrent malignant gliomas: a gene marking and neuropathologic study, in press.
54. Rainov NG, Breakefield XO, Kramm CM. Routes of vector application for brain tumor gene therapy. Gene Ther Mol Biol, in press.
55. Grem JL. 5-Fluoropyrimidines. In Cancer Chemotherapy and Biotherapy: Principles and Practice (2nd edn), Chabner BA, Longo DL (eds). Philadelphia: Lippincott, 1996; 149-212.
56. Hoshino T, Wilson CB, Rosenblum ML, et al. Chemotherapeutic implications of growth fraction and cell cycle time in glioblastomas. J Neurosurg 1975; 43: 127-135.
57. Mullen CA, Kilstrup M, Blaese RM. Transfer of the bacterial gene for cytosine deaminase to mammalian cells confers lethal sensitivity to 5-fluorocytosine: a negative selection system. Proc Natl Acadf Sci U S A 1992; 89: 33-37.
58. Huber BE, Austin EA, Good SS, et al. In vivo antitumor activity of 5-fluorocytosine on human colorectal carcinoma cells genetically modified to express cytosine deaminase. Cancer Res 1993; 53: 4619-4626.
59. Mullen CA, Coale MM, Lowe RM, et al. Tumors expressing the cytosine deaminase suicide gene can be eliminated in vivo with 5-fluorocytosine and induce protective immunity to wild type tumor. Cancer Res 1994; 54: 1503-1506.
60. Mullen CA, Petropoulous D, Lowe RM. Treatment of microscopic pulmonary metastases with recombinant autologous tumor vaccine expressing interleukin 6 and Escherichia coli cytosine deaminase suicide genes. Cancer Res 1996; 56: 1361-1366.
61. Huber BE, Austin EA, Richards CA, et al. Metabolism of 5-fluorocytosine to 5-fluorouracil in human colorectal tumor cells transduced with the cytosine deaminase gene: significant antitumor effects when only a small percentage of tumor cells express cytosine deaminase. Proc Natl Acad Sci U S A 1994; 91: 8302-8306.
62. Holder JW, Elmore E, Barrett JC. Gap junction function and cancer. Cancer Res 1993; 53: 3475-3485.
63. Dong Y, Wen P, Manome Y, et al. In vivo replication-deficient adenovirus vector-mediated transduction of the cytosine deaminase gene sensitizes glioma cells to 5-fluorocytosine. Hum Gene Ther 1996; 7: 713-720.
64. Kievit E, Bershad E, Ng E, et al. Superiority of yeast over bacterial cytosine deaminase for enzyme/prodrug gene therapy in colon cancer xenografts. Cancer Res 1999; 59: 1417-1421.
65. Hamstra DA, Rice DJ, Fahmy S, et al. Enzyme/prodrug therapy for head and neck cancer using a catalytically superior cytosine deaminase. Hum Gene Ther 1999; 10: 1993-2003.
66. Haberkorn U, Oberdorfer F, Gebert J, et al. Monitoring gene therapy with cytosine deaminase: in vitro studies using tritiated-5-fluorocytosine. J Nucl Med 1996; 37: 87-94.
67. Aboagye EO, Artemov D, Senter PD, et al. Intratumoral conversion of 5-fluorocytosine to 5-fluorouracil by monoclonal antibody-cytosine deaminase conjugates: noninvasive detection of prodrug activation by magnetic resonance spectroscopy and spectroscopic imaging. Cancer Res 1998; 58: 4075-4078.
68. Mroz PJ, Moolten FL. Retrovirally transduced Escherichia coli gpt genes combine selectability with chemosensitivity capable of mediating tumor eradication. Hum Gene Ther 1993; 4: 589-595.
69. Tamiya T, Ono Y, Wei MX, et al. Escherichia coli gpt gene sensitizes rat glioma cells to killing by 6-thioxanthine or 6-thioguanine. Cancer Gene Ther 1996; 3: 155-162.
70. Gopferich A, Alonso MJ, Langer R. Development and characterization of microencapsulated microspheres. Pharmacol Res 1994; 11: 1568-1574.
71. Chen L, Waxman D. Intratumoral activation and enhanced Chemotherapeutic effect of oxazaphosphorines following cytochrome P450 gene transfer: development of a combined chemotherapy/cancer gene therapy strategy. Cancer Res 1995; 55: 581-589.
72. Wei MX, Tamiya T, Rhee RJ, et al. Diffusible cytotoxic metabolites contribute to the in vitro bystander effect associated with the cyclophosphamide/cytochrome P450 2B1 cancer gene therapy paradigm. Clin Cancer Res 1995; 1: 1171-1177.
73. Chen L, Waxman DJ, Chen D, et al. Sensitization of human breast cancer cells to cyclophosphamide and ifosfamide by transfer of a liver cytochrome P450 gene. Cancer Res 1996; 56: 1331-1340.
74. Chase M, Chung RY, Chiocca EA. An oncolytic viral mutant that delivers the CYP2B1 transgene and augments cyclophosphamide chemotherapy. Nat Biotechnol 1998; 16: 444-448.
75. Chen L, Yu LJ, Waxman DJ. Potentiation of cytochrome P450/ cyclophosphamide-based cancer gene therapy by coexpression of the P450 reductase gene. Cancer Res 1997; 57: 4830-4837.
76. Jounaidi Y, Hecht JE, Waxman DJ. Retroviral transfer of human cytochrome P450 genes for oxazaphosphorine-based cancer gene therapy. Cancer Res 1998; 58: 4391-4401.
77. Sorscher EJ, Peng S, Bebok Z, et al. Tumor cell bystander killing in colonic carcinoma utilizing the Escherichia coli DeoD gene to generate toxic purines. Gene Ther 1994; 1: 233-238.
78. Parker WB, King SA, Allan PW, et al. In vivo gene therapy of cancer with E. coli purine nucleoside phosphorylase. Hum Gene Ther 1997; 8: 1637-1644.
79. Khan A, Ross WCJ. Tumor growth inhibitory nitrophenylaziridines and related compounds: structure-activity relationships. Chem Biol Interact 1969; 1: 27-47.
80. Venitt S. The differential response of resistant and sensitive strains of Escherichia coli to the cytotoxic effects of 5-aziridino-2,4-dinitrobenzamide (CB1954). Chem Biol Interact 1971; 3: 177-191.
81. Anlezark GM, Melton RG, Sherwood RF, et al. The bioactivation of 5-(azirin-1-yl)-2,4-dinitrobenzamide (CB1954). 1. Purification and properties of a nitroreductase enzyme from Escherichia coli - a potential enzyme for Antibody-Directed Enzyme Prodrug Therapy (ADEPT). Biochem Pharmacol 1992; 44: 2289-2295.
82. Michael NP, Brehm JK, Anlezark GM, et al. Physical characterisation of the Escherichia coli B gene encoding nitroreductase and its overexpression in Escherichia coli K12. FEMS Microbiol Lett 1994; 124: 195-202.
83. Bridgewater JA, Springer CJ, Knox RJ, et al. Expression of the bacterial nitroreductase enzyme in mammalian cells renders them selectively sensitive to killing by the prodrug CB1954. Eur J Cancer 1995; 31A: 2362-2370.
84. Bridgewater JA, Knox RJ, Pitts JD, et al. The bystander effect of the nitroreductase/CB1954 enzyme/prodrug system is due to a cell-permeable metabolite. Hum Gene Ther 1997; 8: 709-717.
85. Friedlos F, Court S, Ford M, et al. Gene-directed enzyme prodrug therapy: quantitative bystander cytotoxicity and DNA damage induced by CB1954 in cells expressing bacterial nitroreductase. Gene Ther 1998; 5: 105-112.
86. Cui W, Gusterson B, Clark AJ. Nitroreductase-mediated cell ablation is very rapid and mediated by a p53-independent apoptotic pathway. Gene Ther 1999; 6: 764-770.
87. Boyd MR, Wilson BJ, Harris TM. Confirmation by chemical synthesis of the structure of 4-ipomeanol, a lung-toxic metabolite of the sweet potato, Ipomoea batatas. Nature New Biol 1972; 236: 158-159.
88. Smith PB, Tiano HF, Nesnow S, et al. 4-Ipomeanol and 2-aminoanthracene: cytotoxicity in C3H/10T half cells expressing rabbit cytochrome P450 4B1. Biochem Pharmacol 1995; 50: 1567-1575.
89. Czerwinski M, McLemore TL, Philpot RM, et al. Metabolic activation of 4-ipomeanol by complementary DNA-expressed human cytochrome P450: evidence for species-specific metabolism. Cancer Res 1991; 51: 4636-4638.
90. Rowinsky EK, Noe DA, Ettinger DS, et al. Phase I and pharmacological study of the pulmonary cytotoxin 4-ipomeanol on a single dose schedule in lung cancer patients. Hepatoxicity is dose limiting in humans. Cancer Res 1993; 53: 1794-1801.
91. Rainov NG, Dobberstein K-U, Sena-Esteves M, et al. New prodrug activation gene therapy for cancer using cytrochrome P450 4B1 and 2-aminoanthracene/4-ipomeanol. Hum Gene Ther 1998; 9: 1261-1273.
92. Vitols KS, Haag-Zeino B, Baer T, et al. Methotrexate-α-phenylalanine: optimization of methotrexate prodrug for activation by carboxypeptidase A-monoclonal antibody conjugate. Cancer Res 1995; 55: 478-480.
93. Hamstra DA, Rehemtulla A. Toward an enzyme/prodrug strategy for cancer gene therapy: endogenous activation of carboxypeptidase A mutants by the PACE/furin family of propeptidases. Hum Gene Ther 1999; 10: 235-248.
94. Scharfmann R, Axelrod JH, Verma IM. Long-term in vivo expression of retrovirus-mediated gene transfer in mouse fibroblast implants. Proc Natl Acad Sci U S A 1991; 88: 4626-4630.
95. Yang L, Hwang R, Chiang Y, et al. Mechanisms for ganciclovir resistance in gastrointestinal tumor cells transduced with a retroviral vector containing the herpes simplex virus thymidine kinase gene. Clin Cancer Res 1998; 4: 731-741.
96. Tripathy SK, Black HD, Goldwasser E, et al. Immune responses to transgene-encoded proteins limit the stability of gene expression after injection of replication-defective adenovirus vectors. Nat Med 1996; 2: 545-550.
97. Patterson AV, Zhang H, Moghaddam A, et al. Modulation of 5-fluoro-2′-deoxyuridine sensitivity in MCF-7 cells transfected with thymidine phosphorylase. Br J Cancer 1995; 72: 669-675.
98. Denning C, Pitts JD. Bystander effects of different enzyme-prodrug systems for cancer gene therapy depend on different pathways for intercellular transfer of toxic metabolites, a factor that will govern clinical choice of appropriate regimes. Hum Gene Ther 1997; 8: 1825-1835.
99. Chottiner EG, Shewach DS, Datta NS, et al. Cloning and expression of human deoxycytidine kinase cDNA. Proc Natl Acad Sci U S A 1991; 88: 1531-1535.
100. Hapke DM, Stegmann APA, Mitchell BS. Retroviral transfer of deoxycytidine kinase into tumor cell lines enhances nucleoside toxicity. Cancer Res 1996; 56: 2343-2347.
101. Manome Y, Wen PY, Dong Y, et al. Viral vector transduction of the human deoxycytidine kinase cDNA sensitizes glioma cells to the cytotoxic effects of cytosine arabinoside in vitro and in vivo. Nat Med 1996; 2: 567-573.
102. Kanai F, Kawakami T, Hamada H, et al. Adenovirus-mediated transduction of Escherichia coli uracil phosphorbiosyltransferase gene sensitizes cancer cells to low concentrations of 5-fluorouracil. Cancer Res 1998; 58: 1946-1951.
103. Danks MK, Morton CL, Pawlik CA, et al. Overexpression of a rabbit liver carboxylesterase sensitizes human tumor cells to CPT-11. Cancer Res 1998; 58: 20-22.
104. Kojima A, Hackett NR, Ohwada A, et al. In vivo human carboxylesterase cDNA gene transfer to activate the prodrug CPT-11 for local treatment of solid tumors. J Clin Invest 1998; 101: 1789-1796.
105. Potter PM, Pawlik CA, Morton CL, et al. Isolation and partial characterization of a cDNA encoding a rabbit liver carboxyl-esterase that activates the prodrug irinotecan (CPT-11). Cancer Res 1998; 58: 2646-2651.
106. Aghi M, Kramm CM, Breakefield XO. Folylpolyglutamyl synthetase gene transfer and glioma antifolate sensitivity in culture and in vivo. J Natl Cancer Inst 1999; 91: 1233-1241.
107. Rogulski KR, Kim JH, Kim SH, et al. Glioma cells transduced with an Escherichia cou CD/HSV-TK fusion gene exhibit enhanced metabolic suicide and radiosensitivity. Hum Gene Ther 1997; 8: 73-85.
108. Aghi M, Kramm CM, Chou TC, et al. Synergistic anticancer effects of ganciclovir/thymidine kinase and 5-fluorocytosine/ cytosine deaminase gene therapies. J Natl Cancer Inst 1998; 90: 370-380.
109. Uckert W, Kammertons T, Haack K, et al. Double suicide gene (cytosine deaminase and herpes simplex virus thymidine kinase) but not single gene transfer allows reliable elimination of tumor cells in vivo. Hum Gene Ther 1998; 9: 855-865.
110. Wang ZH, Zagag D, Zeng B, et al. In vivo and in vitro glioma cell killing induced by an adenovirus expressing both cytosine deaminase and thymidine kinase and its association with interferon-a. J Neuropathol Exp Neurol 1999; 58: 847-858.
111. Palu G, Cavaggioni A, Calvi P, et al. Gene therapy of glioblastoma multiforme via combined expression of suicide and cytokine genes: a pilot study in humans. Gene Ther 1999; 6: 330-337.
112. Aghi M, Chou TC, Suling K, et al. Multimodal cancer treatment mediated by a replicating oncolytic virus that delivers the oxazaphosphorine/rat cytochrome P450 2B1 and ganciclovir/ herpes simplex virus thymidine kinase gene therapies. Cancer Res 1999; 59: 3861-3865.
113. Wildner O, Blaese RM, Morris JC. Synergy between the herpes simplex virus tk/ganciclovir prodrug suicide system and the topoisomerase I inhibitor topotecan. Hum Gene Ther 1999; 10: 2679-2687.
114. Kroll RA, Neuwelt EA. Outwitting the blood brain barrier for therapeutic purposes: osmotic opening and other means. Neurosurgery 1998; 42: 1083-1100.
115. Bartus RT. The blood brain barrier as a target for pharmacological modulation. Curr Opin Drug Discov Dev 1999; 2: 152-167.
116. Aboody KS, Rainov N, Bower KA, et al. A new platform for gene therapy against brain tumors: foreign gene expressing neural stem cells display tropism for intracranial gliomas, submitted.
117. Chen MY, Lonser RR, Morrison PF, Governale LS, Oldfield EH. Variables affecting convection-enhanced delivery to the striatum: a systematic examination of rate of infusion, cannula size, infusate concentration, and tissue-cannula sealing time. J Neurosurg 1999; 90: 315-320.
118. Gu DL, Gonzalez AM, Printz MA, et al. Fibroblast growth factor 2 retargeted adenovirus has redirected cellular tropism: evidence for reduced toxicity and enhanced antitumor activity in mice. Cancer Res 1999; 59: 2608-2614.
119. Lynch WP, Sharpe AH, Snyder EY. Neural stem cells as engraftable packaging lines optimize viral vector-mediated gene delivery to the CNS: evidence from studying retroviral env-related neurodegeneration. J Virol 1999; 73: 6841-6851.
120. Sena-Esteves M, Saeki Y, Camp S, et al. Single step conversion of cells to retrovirus vector producers with herpes simplex virus-Epstein Barr virus hybrid amplicons. J Virol 1999; 73: 10426-10439.
121. Connors TA. The choice of prodrugs for gene directed enzyme prodrug therapy of cancer. Gene Ther 1995; 2: 702-709.
122. Tew KD, Colvin M, Chabner BA. Alkylating agents. In Cancer Chemotherapy and Biotherapy: Principles and Practice (2nd edn), Chabner BA, Longo DL, (eds). Philadelphia: Lippincott, 1996; 297-332.
123. Ono Y, Ikeida K, Wei MX, et al. Regression of experimental brain tumors with 6-thioxanthine and Escherichia coli gpt gene therapy. Hum Gene Ther 1997; 8: 2043-2055.
124. Wei MX, Tamiya T, Chase M, et al. Experimental tumor therapy in mice using the cyclophosphamide-activating cytochrome P450 2B1 gene. Hum Gene Ther 1994; 5: 969-978.
125. Walker MD, Alexander E Jr, Hunter WE, et al. Evaluation of ECNU and/or radiotherapy in the treatment of anaplastic gliomas. J Neurosurg 1978; 49: 333-343.
126. Allen JC, Helson L. High dose cyclophosphamide chemotherapy for recurrent CNS tumors. J Neurosurg 1981; 55: 749-756.
127. Gabbai AA, Hochberg FH, Linggood RM, et al. High dose mehtotrexate for non-AIDS primary central nervous system lymphoma. J Neurosurg 1989; 70: 190-194.
128. Yung WK, Prados MD, Yaya-Tur R, et al. Multicenter phase II trial of temoxolamide in patients with anaplastic astrocytoma at first relapse. J Clin Oncol 1999; 17: 2762-2771.
129. O'Reilly SM, Newlands ES, Glasers MG, et al. Temozolamide: a new oral cystotoxic chemotherapeutic agent with promising activity against primary brain tumors. Eur J Cancer 1993; 29A: 940-942.